- Home
- NUVL vs URBN Comparison
NUVL vs URBN Comparison
Compare NUVL & URBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- URBN
- Stock Information
- Founded
- NUVL 2017
- URBN 1970
- Country
- NUVL United States
- URBN United States
- Employees
- NUVL N/A
- URBN N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- URBN Clothing/Shoe/Accessory Stores
- Sector
- NUVL Health Care
- URBN Consumer Discretionary
- Exchange
- NUVL Nasdaq
- URBN Nasdaq
- Market Cap
- NUVL 5.8B
- URBN 6.8B
- IPO Year
- NUVL 2021
- URBN 1993
- Fundamental
- Price
- NUVL $78.64
- URBN $70.09
- Analyst Decision
- NUVL Strong Buy
- URBN Buy
- Analyst Count
- NUVL 11
- URBN 11
- Target Price
- NUVL $120.91
- URBN $81.91
- AVG Volume (30 Days)
- NUVL 390.3K
- URBN 2.3M
- Earning Date
- NUVL 11-11-2025
- URBN 08-27-2025
- Dividend Yield
- NUVL N/A
- URBN N/A
- EPS Growth
- NUVL N/A
- URBN 55.85
- EPS
- NUVL N/A
- URBN 5.10
- Revenue
- NUVL N/A
- URBN $5,832,231,000.00
- Revenue This Year
- NUVL N/A
- URBN $10.58
- Revenue Next Year
- NUVL N/A
- URBN $6.73
- P/E Ratio
- NUVL N/A
- URBN $13.74
- Revenue Growth
- NUVL N/A
- URBN 9.63
- 52 Week Low
- NUVL $55.54
- URBN $34.76
- 52 Week High
- NUVL $110.00
- URBN $80.71
- Technical
- Relative Strength Index (RSI)
- NUVL 51.21
- URBN 45.67
- Support Level
- NUVL $77.88
- URBN $67.42
- Resistance Level
- NUVL $83.09
- URBN $72.06
- Average True Range (ATR)
- NUVL 3.14
- URBN 3.21
- MACD
- NUVL 0.14
- URBN -0.06
- Stochastic Oscillator
- NUVL 48.79
- URBN 34.00
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About URBN Urban Outfitters Inc.
Founded in 1970, Philadelphia-based Urban Outfitters is an apparel and home goods retailer that operates more than 700 stores and e-commerce in the United States, which accounts for about 87% of sales, and other regions. Its retail nameplates are Urban Outfitters (23% of fiscal 2025 sales), Free People/Movement (26%), and Anthropologie (44%). Retail accounted for 88% of fiscal 2025 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (7% of sales). Urban Outfitters primarily markets to young adults and offers products in categories such as apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.